FTC Clears Teva's $40.5B Generics Buy With Divestitures
The Federal Trade Commission said Wednesday it will allow Teva to move forward with its planned $40.5 billion acquisition of Allergan's generic business, provided that the Israel-based generics giant sells the rights...To view the full article, register now.
Already a subscriber? Click here to view full article